CSL Aktie

CSL Investeringar

Delisted·19 juni 2026

Totala investeringar för CSL (CSL.AX) per 23 aug. 2026 är 203,00 M USD. Föregående år var Totala investeringar 163,00 M USD — en förändring på 24,54 % (högre).

Investeringar

203,00 MUSD

YoY

24,54%

Senast uppdaterad:

Totala investeringar för CSL är 2026 203,00 M USD. Totala investeringar för CSL var 2025 163,00 M USD. Det minskar därmed med 24,54% högre jämfört med året innan.

CSL Investeringar Historik

  • 3 år

  • 10 år

  • 25 år

  • Max

Investeringar
Date
Investeringar
1 jan. 2018
6,20 M USD
1 jan. 2019
9,90 M USD
1 jan. 2020
14,20 M USD
1 jan. 2021
21,50 M USD
1 jan. 2022
402,90 M USD
1 jan. 2023
173,00 M USD
1 jan. 2024
163,00 M USD
1 jan. 2025
203,00 M USD
CSL Investeringar Historik
ÅRInvesteringarYoY
203,00 MUSD+24,54%
163,00 MUSD−5,78%
173,00 MUSD−57,06%
402,90 MUSD+1 773,95%
21,50 MUSD+51,41%
14,20 MUSD+43,43%
9,90 MUSD+59,68%
6,20 MUSD+58,97%
3,90 MUSD+34,48%
2,90 MUSD+480,00%
500 000,00USD−50,00%
1,00 MUSD
Access this data via the Eulerpool API

CSL Aktieanalys

Vad gör CSL? CSL Ltd is a global leading company in the field of biological medicine, manufacturing a wide range of products used in the therapy of diseases. The company is based in Melbourne, Australia, and is one of the largest biotech companies in the country. CSL was founded in 1916 by Australian researcher Frank Macfarlane Burnet. Originally named Commonwealth Serum Laboratories, the company focused on the research and production of vaccines. CSL was then privatized in 1994 and changed its name to CSL Ltd. CSL's business model is based on the production of protein products and plasma derivatives used in immunotherapy, hematology, and transplantation medicine. The company specializes in the production and marketing of products in three main areas: plasma products, vaccines, and animal health. CSL's plasma division includes a variety of products, including intravenous immunoglobulins (IVIG), platelets, and alpha-1 antitrypsin. The company operates a number of plasma centers in the US and Europe to collect raw materials for these products. In the vaccine sector, CSL is primarily involved in the manufacture of influenza vaccines and also offers a range of other vaccines, including vaccines against snake bites and encephalitis. In the field of animal health, CSL produces animal vaccines to prevent viral infections in livestock such as pigs, poultry, and cattle. CSL is committed to research and development to develop new products and improve existing ones. The company has a long history in the research and development of vaccines and immunotherapies and has established a strong presence in this field. The company employs over 27,000 people in 35 countries worldwide and operates production facilities in Australia, the US, Europe, and Asia. CSL's headquarters are located in Parkville, a suburb of Melbourne, Australia. CSL has an impressive track record in terms of growth and profitability and is a stable market leader in its field. The company has achieved solid growth rates in recent years and generated a revenue of $8.5 billion in 2019. CSL is a key player in the global healthcare industry and has established a reputation as a reliable supplier of medical products and services. The company is committed to developing innovative solutions to advance medical progress and make a positive contribution to human health. CSL är ett av de mest populära företagen på Eulerpool.

Vanliga frågor om CSL-aktien

Totala investeringar för CSL är 203,00 M USD år 2026.

Totala investeringar för CSL förändrades från 163,00 M USD till 203,00 M USD, vilket motsvarar en förändring på 24,54 %. Värdet är högre än föregående år.

På Eulerpool kan du hitta den fullständiga historiska utvecklingen av Totala investeringar CSL sedan 2006 – med årliga värden, diagram och detaljerad analys.

Totala investeringar inkluderar både kortfristiga och långfristiga värdepapper som innehas av företaget.

Totala investeringars USD är en nyckelfaktor för investerare. Förändringar i denna nyckeltal kan signalera förbättrande eller försämrande fundamentala förhållanden, vilket direkt påverkar aktiekursen. På Eulerpool kan du följa Totala investeringars CSL historiskt och i realtid.

Access this data via the Eulerpool API

Balansräkning — CSL

Alla nyckeltal — CSL